^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

MLL rearrangement

i
Other names: HTRX1, HTRX, MLL1A, Mixed Lineage Leukemia 1, Myeloid/Lymphoid Or Mixed-Lineage Leukemia Protein 1, CXXC7, MLL1, TRX1, Zinc Finger Protein HRX, Trithorax-Like Protein, ALL-1, Lysine (K)-Specific Methyltransferase 2A, CXXC-Type Zinc Finger Protein 7, Histone-Lysine N-Methyltransferase 2A, Myeloid/Lymphoid Or Mixed-Lineage Leukemia, Lysine Methyltransferase 2A, MLL, Myeloid/Lymphoid Or Mixed-Lineage Leukemia, KMT2A
Phase 2
Fred Hutchinson Cancer Center
Recruiting
Last update posted :
06/07/2024
Initiation :
07/06/2024
Primary completion :
10/31/2024
Completion :
10/31/2025
KMT2A • HLA-DRB1 • HLA-B
|
MLL rearrangement • MLL rearrangement
|
cyclophosphamide • fludarabine IV • thiotepa • cyclosporin A microemulsion
Phase 1
Memorial Sloan Kettering Cancer Center
Active, not recruiting
Last update posted :
06/05/2024
Initiation :
05/01/2013
Primary completion :
05/01/2025
Completion :
05/01/2025
KMT2A • IKZF1
|
MLL rearrangement • IKZF1 deletion
|
cyclophosphamide • vadacabtagene leraleucel (JCAR015)
Phase 1
National Cancer Institute (NCI)
Recruiting
Last update posted :
06/05/2024
Initiation :
11/10/2024
Primary completion :
12/31/2027
Completion :
12/31/2027
FLT3 • NPM1 • KMT2A
|
FLT3-ITD mutation • FLT3 mutation • NPM1 mutation • MLL rearrangement • FLT3 wild-type • MLL mutation
|
daunorubicin • Revuforj (revumenib) • Starasid (cytarabine ocfosfate)
Phase 1
Kura Oncology, Inc.
Recruiting
Last update posted :
05/30/2024
Initiation :
02/22/2024
Primary completion :
08/01/2026
Completion :
08/01/2027
FLT3 • NPM1 • KMT2A
|
FLT3 mutation • NPM1 mutation • KMT2A rearrangement • MLL rearrangement • KMT2A mutation • MLL mutation
|
cytarabine • Xospata (gilteritinib) • idarubicin hydrochloride • ziftomenib (KO-539) • fludarabine IV
Phase 2
Children's Oncology Group
Recruiting
Last update posted :
05/30/2024
Initiation :
06/19/2017
Primary completion :
03/31/2026
Completion :
03/31/2026
KMT2A • CD22
|
MLL rearrangement • CD22 expression
|
cytarabine • cyclophosphamide • methotrexate • Besponsa (inotuzumab ozogamicin) • vincristine • leucovorin calcium • Oncaspar liquid (pegaspargase) • mercaptopurine delayed release (DR6MP) • mercaptopurine • Asparlas (calaspargase pegol-mknl) • Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn) • Starasid (cytarabine ocfosfate) • cyclophosphamide intravenous
Phase 1
University College, London
Active, not recruiting
Last update posted :
05/30/2024
Initiation :
04/01/2016
Primary completion :
12/31/2028
Completion :
12/31/2036
ABL1 • BCR • KMT2A • IGH • CD22 • TCF3
|
KMT2A rearrangement • MLL rearrangement
|
cyclophosphamide • fludarabine IV • AUTO1/22 • cyclophosphamide intravenous
Phase 1/2
Sidney Kimmel Comprehensive Cancer Center at Jo...
Active, not recruiting
Last update posted :
05/27/2024
Initiation :
09/05/2017
Primary completion :
06/30/2025
Completion :
06/30/2025
KMT2A
|
MLL rearrangement
|
Blincyto (blinatumomab) • dexamethasone
Phase 3
National Cancer Institute (NCI)
Active, not recruiting
Last update posted :
05/24/2024
Initiation :
02/29/2012
Primary completion :
12/31/2022
Completion :
09/22/2024
ABL1 • BCR • RUNX1 • KMT2A • ETV6
|
MLL rearrangement • MLL rearrangement
|
dasatinib • cytarabine • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • methotrexate • vincristine • prednisone • daunorubicin • clofarabine • leucovorin calcium • Oncaspar liquid (pegaspargase) • mercaptopurine delayed release (DR6MP) • mercaptopurine • thioguanine • Hemady (dexamethasone tablets) • Starasid (cytarabine ocfosfate) • cyclophosphamide intravenous
Phase 2
Memorial Sloan Kettering Cancer Center
Recruiting
Last update posted :
05/24/2024
Initiation :
11/20/2020
Primary completion :
12/20/2025
Completion :
12/20/2025
KMT2A
|
MLL rearrangement • MLL rearrangement
|
clofarabine • fludarabine IV • busulfan • cyclosporin A microemulsion
Phase 2
Memorial Sloan Kettering Cancer Center
Completed
Last update posted :
05/22/2024
Initiation :
12/01/2013
Primary completion :
09/27/2023
Completion :
09/27/2023
FLT3 • KMT2A
|
FLT3 mutation • MLL rearrangement
|
azacitidine
Phase 1/2
Syndax Pharmaceuticals
Recruiting
Last update posted :
05/17/2024
Initiation :
11/05/2019
Primary completion :
12/01/2024
Completion :
12/01/2024
KMT2A • NUP98
|
NPM1 mutation • MLL rearrangement • MLL rearrangement • NUP98 rearrangement
|
Revuforj (revumenib) • Tybost (cobicistat)
Phase 1
Syndax Pharmaceuticals
Active, not recruiting
Last update posted :
05/17/2024
Initiation :
03/09/2022
Primary completion :
05/01/2024
Completion :
06/01/2024
KMT2A • NUP98
|
KMT2A rearrangement • MLL rearrangement
|
cytarabine • cyclophosphamide • Revuforj (revumenib)
Phase 1
Kura Oncology, Inc.
Recruiting
Last update posted :
05/16/2024
Initiation :
07/18/2023
Primary completion :
05/01/2026
Completion :
05/01/2027
NPM1 • KMT2A
|
NPM1 mutation • KMT2A rearrangement • MLL rearrangement • KMT2A mutation • MLL mutation
|
Venclexta (venetoclax) • azacitidine • daunorubicin • ziftomenib (KO-539)
Phase 2
Masonic Cancer Center, University of Minnesota
Recruiting
Last update posted :
05/07/2024
Initiation :
05/01/2023
Primary completion :
10/22/2027
Completion :
10/22/2028
NPM1 • KMT2A • IKZF1 • HLA-DRB1 • CEBPA • HLA-B • HLA-C
|
NPM1 mutation • MLL rearrangement • MLL rearrangement • CEBPA mutation
|
cyclophosphamide • sirolimus • fludarabine IV
Phase 2
Memorial Sloan Kettering Cancer Center
Recruiting
Last update posted :
05/02/2024
Initiation :
05/22/2023
Primary completion :
05/22/2028
Completion :
05/22/2028
KMT2A
|
MLL rearrangement • MLL rearrangement
|
cyclophosphamide
Phase 2
Pfizer
Recruiting
Last update posted :
04/30/2024
Initiation :
05/17/2023
Primary completion :
07/11/2028
Completion :
07/09/2031
TP53 • KMT2A • CD22 • TCF3 • PBX1
|
KMT2A rearrangement • MLL rearrangement • CD22 positive
|
Besponsa (inotuzumab ozogamicin)
Phase 1/2
LLS PedAL Initiative, LLC
Recruiting
Last update posted :
04/22/2024
Initiation :
04/18/2022
Primary completion :
12/31/2026
Completion :
12/31/2026
KMT2A
|
KMT2A rearrangement • MLL rearrangement
Phase 2
Children's Oncology Group
Recruiting
Last update posted :
04/22/2024
Initiation :
01/08/2024
Primary completion :
12/31/2027
Completion :
12/31/2027
KMT2A
|
MLL rearrangement
|
cytarabine • methotrexate • vincristine • Revuforj (revumenib) • Oncaspar liquid (pegaspargase) • fludarabine IV • Asparlas (calaspargase pegol-mknl) • Starasid (cytarabine ocfosfate)
Phase 2
Masonic Cancer Center, University of Minnesota
Recruiting
Last update posted :
04/16/2024
Initiation :
03/30/2018
Primary completion :
01/10/2025
Completion :
11/10/2025
NPM1 • KMT2A • IKZF1 • CEBPA
|
NPM1 mutation • MLL rearrangement • MLL rearrangement • CEBPA mutation
|
cyclophosphamide
Phase 2
Masonic Cancer Center, University of Minnesota
Active, not recruiting
Last update posted :
04/10/2024
Initiation :
01/02/2019
Primary completion :
06/23/2020
Completion :
06/28/2024
FLT3 • NPM1 • KMT2A • HLA-DRB1 • CEBPA
|
FLT3-ITD mutation • NPM1 mutation • MLL rearrangement • MLL rearrangement • CEBPA mutation • FLT3 wild-type
|
cyclophosphamide • melphalan • fludarabine IV • busulfan • cyclophosphamide intravenous • spanlecortemlocel (MGTA-456)
Phase 1
OHSU Knight Cancer Institute
Recruiting
Last update posted :
04/09/2024
Initiation :
01/14/2021
Primary completion :
08/01/2025
Completion :
02/01/2026
TP53 • FLT3 • ABL1 • BCR • EZH2 • RUNX1 • SF3B1 • ASXL1 • KMT2A • SRSF2 • BCOR • U2AF1 • STAG2 • MECOM • NUP214 • GATA2 • MLLT3 • CDKN1A • DEK • ZRSR2
|
TP53 mutation • FLT3 mutation • RUNX1 mutation • ASXL1 mutation • EZH2 mutation • MLL rearrangement • SRSF2 mutation • U2AF1 mutation • BCOR mutation • Chr del(5q) • STAG2 mutation • FLT3 wild-type • Chr t(9;11) • ZRSR2 mutation
|
cytarabine • Pemazyre (pemigatinib) • daunorubicin • Starasid (cytarabine ocfosfate)
Phase 3
Princess Maxima Center for Pediatric Oncology
Recruiting
Last update posted :
04/05/2024
Initiation :
12/15/2022
Primary completion :
09/01/2027
Completion :
09/01/2030
KMT2A
|
KMT2A rearrangement • MLL rearrangement
|
Blincyto (blinatumomab)
Phase 1
Andrew E. Place, MD
Recruiting
Last update posted :
04/02/2024
Initiation :
03/29/2023
Primary completion :
04/02/2025
Completion :
04/02/2027
FLT3 • ABL1 • BCR • BCL2 • KMT2A • IKZF1
|
KMT2A rearrangement • MLL rearrangement • IKZF1 deletion • ABL1 fusion • ABL1 deletion
|
Venclexta (venetoclax) • cytarabine • doxorubicin hydrochloride • azacitidine • vincristine • leucovorin calcium • Asparlas (calaspargase pegol-mknl) • dexrazoxane
Phase 1
Epizyme, Inc.
Completed
Last update posted :
03/26/2024
Initiation :
09/01/2012
Primary completion :
11/01/2015
Completion :
02/01/2016
KMT2A
|
MLL rearrangement
|
pinometostat (EPZ-5676)
Phase 2
National Cancer Institute (NCI)
Active, not recruiting
Last update posted :
03/25/2024
Initiation :
04/01/2017
Primary completion :
09/30/2020
Completion :
09/22/2024
KMT2A
|
KMT2A rearrangement • MLL rearrangement
|
cytarabine • azacitidine • cyclophosphamide • methotrexate • vincristine • daunorubicin • leucovorin calcium • Oncaspar liquid (pegaspargase) • mercaptopurine • thioguanine • Hemady (dexamethasone tablets) • Starasid (cytarabine ocfosfate) • cyclophosphamide intravenous
Phase 3
Mats Heyman
Recruiting
Last update posted :
03/19/2024
Initiation :
07/13/2020
Primary completion :
06/30/2027
Completion :
06/30/2032
MYC • BCL2 • KMT2A
|
MYC rearrangement + BCL2 rearrangement • MLL rearrangement • MYC rearrangement • MYC translocation • BCL2 rearrangement
|
imatinib • doxorubicin hydrochloride • Blincyto (blinatumomab) • Besponsa (inotuzumab ozogamicin) • vincristine • thioguanine
Phase 1/2
Sidney Kimmel Comprehensive Cancer Center at Jo...
Recruiting
Last update posted :
03/13/2024
Initiation :
09/01/2010
Primary completion :
09/01/2025
Completion :
12/01/2025
FLT3 • KMT2A • HLA-DRB1 • HLA-DQB1 • HLA-B • HLA-C
|
Chr del(17p) • Chr del(11q) • MLL rearrangement • MLL rearrangement • Chr t(9;11)
|
cyclophosphamide • sirolimus • fludarabine IV • cyclophosphamide intravenous
Phase 1
Washington University School of Medicine
Recruiting
Last update posted :
03/11/2024
Initiation :
11/03/2022
Primary completion :
11/30/2027
Completion :
11/30/2027
FLT3 • NPM1 • RUNX1 • KMT2A • ETV6 • CD38 • CREBBP • NUP98 • AFF1 • HLA-DRB1 • PTPRC • HLA-DQB1 • MECOM • NCAM1 • NUP214 • TCF3 • FUS • HLA-B • KAT6A • DEK • AFDN • EGR1 • MLLT10
|
MLL rearrangement • NUP98 rearrangement
Phase 2
City of Hope Medical Center
Recruiting
Last update posted :
03/06/2024
Initiation :
02/07/2020
Primary completion :
08/04/2025
Completion :
08/04/2025
FLT3 • CD8 • HLA-DRB1 • CD4 • NCAM1
|
MLL rearrangement
|
cyclophosphamide • fludarabine IV • cyclophosphamide intravenous
Phase 2
Memorial Sloan Kettering Cancer Center
Active, not recruiting
Last update posted :
03/04/2024
Initiation :
02/07/2018
Primary completion :
02/07/2025
Completion :
02/07/2025
KMT2A
|
MLL rearrangement • MLL rearrangement
|
Actemra IV (tocilizumab) • cyclosporine • Neupogen (filgrastim)
Phase 1
City of Hope Medical Center
Recruiting
Last update posted :
02/22/2024
Initiation :
07/06/2018
Primary completion :
11/11/2028
Completion :
11/11/2028
FLT3 • NPM1 • HLA-DRB1 • HLA-B • HLA-C
|
MLL rearrangement
|
melphalan • fludarabine IV
Phase 1/2
BioNova Pharmaceuticals (Shanghai) LTD.
Recruiting
Last update posted :
02/21/2024
Initiation :
09/16/2023
Primary completion :
06/01/2026
Completion :
06/01/2027
NPM1 • KMT2A
|
NPM1 mutation • KMT2A rearrangement • MLL rearrangement • KMT2A mutation • MLL mutation
Phase 1
Dr. Melody Smith, MD, MS
Recruiting
Last update posted :
02/20/2024
Initiation :
08/18/2022
Primary completion :
01/01/2037
Completion :
01/01/2037
CD19 • KMT2A • CRLF2 • CD22 • HLA-DRB1 • HLA-B • HLA-C
|
KMT2A rearrangement • MLL rearrangement • CD19 expression • CRLF2 rearrangement
|
Orca-T • firicabtagene autoleucel (CRG-022)
Phase 1/2
M.D. Anderson Cancer Center
Recruiting
Last update posted :
02/16/2024
Initiation :
04/08/2022
Primary completion :
06/01/2024
Completion :
06/01/2024
TP53 • FLT3 • ABL1 • BCR • NPM1 • RUNX1 • ASXL1 • KMT2A • MECOM • NUP214 • GATA2 • DEK
|
TP53 mutation • FLT3 mutation • RUNX1 mutation • ASXL1 mutation • MLL rearrangement • Chr del(5q) • FLT3 wild-type
|
cyclophosphamide • melphalan • fludarabine IV • mesna • Neupogen (filgrastim) • cyclophosphamide intravenous
Phase 1
City of Hope Medical Center
Recruiting
Last update posted :
01/30/2024
Initiation :
07/19/2022
Primary completion :
12/13/2024
Completion :
12/13/2024
FLT3 • NPM1 • IL2RA • ISG20
|
MLL rearrangement • IL2RA expression • Chr t(9;11)
|
melphalan • fludarabine IV • Kepivance (palifermin) • Simulect (basiliximab)
Phase 1
Jacqueline Garcia, MD
Recruiting
Last update posted :
01/26/2024
Initiation :
10/24/2018
Primary completion :
02/01/2025
Completion :
02/01/2026
KRAS • TP53 • FLT3 • ABL1 • NRAS • BCR • BCL2 • NPM1 • NF1 • RUNX1 • SF3B1 • ASXL1 • KMT2A • PTPN11 • SRSF2 • BCOR • U2AF1 • STAG2 • MECOM • NUP214 • GATA2 • DEK • RIT1 • ZRSR2
|
TP53 mutation • KRAS mutation • NRAS mutation • RUNX1 mutation • RAS mutation • ASXL1 mutation • CBL mutation • MLL rearrangement • U2AF1 mutation • Chr del(5q) • FLT3 wild-type
|
Venclexta (venetoclax) • azacitidine • Inqovi (decitabine/cedazuridine) • fludarabine IV • busulfan
Phase 2
Masonic Cancer Center, University of Minnesota
Recruiting
Last update posted :
01/26/2024
Initiation :
11/01/2005
Primary completion :
12/01/2025
Completion :
12/01/2025
KMT2A
|
MLL rearrangement • MLL rearrangement
|
melphalan • fludarabine IV • busulfan • cyclosporine • Neupogen (filgrastim)
Phase 1
Children's Hospital Medical Center, Cincinnati
Recruiting
Last update posted :
01/25/2024
Initiation :
12/27/2018
Primary completion :
01/01/2025
Completion :
01/01/2026
KMT2A
|
MLL rearrangement
|
Venclexta (venetoclax) • Vyxeos (cytarabine/daunorubicin liposomal formulation)
Phase 1/2
St. Petersburg State Pavlov Medical University
Active, not recruiting
Last update posted :
01/04/2024
Initiation :
04/01/2021
Primary completion :
04/01/2023
Completion :
04/01/2024
TP53 • FLT3 • KMT2A • NUP98
|
TP53 mutation • MLL rearrangement
Phase 1
City of Hope Medical Center
Active, not recruiting
Last update posted :
01/03/2024
Initiation :
06/25/2015
Primary completion :
06/15/2024
Completion :
06/15/2024
FLT3 • HLA-DRB1
|
MLL rearrangement • Chr t(9;11)
|
cyclophosphamide • fludarabine IV • cyclophosphamide intravenous
Phase 2
Stephan Grupp MD PhD
Recruiting
Last update posted :
12/19/2023
Initiation :
03/12/2020
Primary completion :
03/10/2028
Completion :
03/10/2037
CD19 • KMT2A
|
MLL rearrangement • CD19 expression
|
Kymriah (tisagenlecleucel-T)
Phase N/A
Universitair Ziekenhuis Brussel
Completed
Last update posted :
12/06/2023
Initiation :
11/01/2010
Primary completion :
09/01/2018
Completion :
09/01/2018
FLT3 • KMT2A
|
MLL rearrangement • MLL rearrangement